Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Research Article

The Development and Validation of Simultaneous Quantitative Analysis Reversed-phase High-performance Liquid Chromatography for Sitagliptin Phosphate Monohydrate and Dapagliflozin Propanediol Monohydrate Fixed-dose Combination Dual-layered Tablet

Author(s): So-Jin Kang and Joo-Eun Kim*

Volume 19, Issue 5, 2023

Published on: 18 April, 2023

Page: [423 - 431] Pages: 9

DOI: 10.2174/1573412919666230417081123

Price: $65

Abstract

Background: Sitagliptin phosphate monohydrate-dapagliflozin propanediol hydrate fixeddose combination (FDC) dual-layered tablet is used for type 2 diabetes treatment. Simultaneous quantitative analysis can shorten the analysis time of sitagliptin phosphate monohydrate-dapagliflozin propanediol monohydrate FDC dual-layered tablets and increase their efficiency.

Objective: This study aimed to develop the simultaneous quantitative analysis for sitagliptin phosphate monohydrate-dapagliflozin propanediol monohydrate FDC dual-layered tablet, a type 2 diabetes treatment.

Methods: Simultaneous quantitative analysis using the rapid and selective reversed-phase highperformance liquid chromatography (RP-HPLC) method was developed and validated using method validation. RP-HPLC analysis was conducted using an ultraviolent absorption spectrophotometer and a Zorbax C18 column (4.6 x 150 mm, 5 μm). The flow rate and injection volume were set to 1.5 mL min-1 and 20 μL, respectively. The wavelength was set at 205 nm.

Results: The retention times of sitagliptin phosphate monohydrate and dapagliflozin propanediol monohydrate were 2.28 mins and 10.65 mins, respectively. The relative standard deviations of the system suitability for validation of simultaneous quantitative analysis were 0.03% for sitagliptin phosphate monohydrate and dapagliflozin propanediol monohydrate. The chromatogram confirmed that there was no peak interference between the two main components and between the main component and the excipients. In addition, It revealed a favorable linearity with correlation coefficients of 0.9999 in the concentration range of 20-120% compared to the standard solution.

Conclusion: The developed simultaneous quantitative analysis shortened the analysis time and high efficiency of the sitagliptin phosphate monohydrate-dapagliflozin propanediol monohydrate FDC bilayer tablet. The validity of the analytical method was verified through accuracy and precision, detection and quantitation limits, and solution stability tests. In addition, it was thought that it would be helpful in developing an analytical method by referring to the simultaneous quantitative analysis method for developing other FDC dual-layered tablets.

« Previous Next »
Graphical Abstract

[1]
Gallwitz, B. Review of sitagliptin phosphate: A novel treatment for type 2 diabetes. Vasc. Health Risk Manag., 2007, 3(2), 203-210.
[http://dx.doi.org/10.2147/vhrm.2007.3.2.203] [PMID: 17580730]
[2]
Xu, B.; Shen, T.; Chen, L.; Xia, J.; Zhang, C.; Wang, H.; Yu, M.; Lei, T. The effect of sitagliptin on lipid metabolism of fatty liver mice and related mechanisms. Med. Sci. Monit., 2017, 23, 1363-1370.
[http://dx.doi.org/10.12659/MSM.900033] [PMID: 28315901]
[3]
Picatoste, B.; Ramírez, E.; Caro-Vadillo, A.; Iborra, C.; Egido, J.; Tuñón, J.; Lorenzo, Ó.; Lorenzo, O. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS One, 2013, 8(10), e78330.
[http://dx.doi.org/10.1371/journal.pone.0078330] [PMID: 24302978]
[4]
Zerilli, T.; Pyon, E. Sitagliptin phosphate: A DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin. Ther., 2007, 29(12), 2614-2634.
[http://dx.doi.org/10.1016/j.clinthera.2007.12.034] [PMID: 18201579]
[5]
Nathan, K.T.; Ahmed-Sarwar, N.; Werner, P. SGLT-2 inhibitors: A novel mechanism in targeting glycemic control in type 2 diabetes mellitus. Consult. Pharm., 2016, 31(5), 251-260.
[http://dx.doi.org/10.4140/TCP.n.2016.260] [PMID: 27178654]
[6]
Moses, R.; Colagiuri, S.; Pollock, C. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. Australas. Med. J., 2014, 7(10), 405-415.
[http://dx.doi.org/10.4066/AMJ.2014.2181] [PMID: 25379062]
[7]
Ganorkar, S.B.; Sharma, S.S.; Patil, M.R.; Bobade, P.S.; Dhote, A.M.; Shirkhedkar, A.A. Pharmaceutical analytical profile for novel SGL-2 inhibitor: Dapagliflozin. Crit. Rev. Anal. Chem., 2020, 51(8), 1-13.
[http://dx.doi.org/10.1080/10408347.2020.1777524] [PMID: 32544345]
[8]
Pathak, S; Mishra, P. A Review on analytical methods of dapagliflozin: An update. Int. J. Pharmaceut. Quality Assurance, 2020, 11(3), 355-360.
[9]
Jabbour, S.A.; Hardy, E.; Sugg, J.; Parikh, S.; Group, S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabet., Care, 2014, 37(3), 740-750.
[http://dx.doi.org/10.2337/dc13-0467] [PMID: 24144654]
[10]
Bockstaele, E.; Taverniers, I.; Loose, M. Analytical Method Validation and Quality Assurance. Pharmaceutical Sciences Encyclopedia: Drug Discovery; Development, and Manufacturing, 2010, 743-789.
[http://dx.doi.org/10.1002/9780470259832.ch23]
[11]
Kazi, M.; Alqahtani, A.A.; Alsaadi, B.S.; Alkholief, M.; Alanazi, F.K. UHPLC method development for determining sitagliptin and dapagliflozin in lipid-based self-nanoemulsifying systems as combined dose in commercial products and its application to pharmacokinetic study of dapagliflozin in rats. Pharm. Chem. J., 2019, 53(1), 79-87.
[http://dx.doi.org/10.1007/s11094-019-01959-4]
[12]
Shabir, G.A.; John Lough, W.; Arain, S.A.; Bradshaw, T.K. Evaluation and application of best practice in analytical method validation. J. Liq. Chromatogr. Relat. Technol., 2007, 30(3), 311-333.
[http://dx.doi.org/10.1080/10826070601084753]
[13]
Debata, J; Kumar, S; Jha, SK; Khan, A A New RP-HPLC method development and validation of dapagliflozin in bulk and tablet dosage form. Int. J. Drug Develop. Research, 2017, 9, 2.
[14]
Vidushi, Y.; Meenakshi, B.; Bharkatiya, M. A review on HPLC method development and validation. Res. J. Life Sci. Bioinform. Pharm. Chem. Sci., 2017, 2, 178.
[15]
Shah, B.P.; Jain, S.; Prajapati, K.K.; Mansuri, N.Y. Stability indicating HPLC method development: A review. Int. J. Pharm. Sci. Res., 2012, 3, 2978.
[16]
Sahu, P.K.; Ramisetti, N.R.; Cecchi, T.; Swain, S.; Patro, C.S.; Panda, J. An overview of experimental designs in HPLC method development and validation. J. Pharm. Biomed. Anal., 2018, 147, 590-611.
[http://dx.doi.org/10.1016/j.jpba.2017.05.006] [PMID: 28579052]
[17]
Choi, M.N.; Park, Y.J.; Kim, J.E. Development and validation of a reversed-phase high Performance liquid chromatography method for the simultaneous estimation of rosuvastatin calcium and telmisartan in fixed-dose complex dual-layer tablets in six dosage forms. Indian J. Pharm. Sci., 2021, 83(3), 451-464.
[http://dx.doi.org/10.36468/pharmaceutical-sciences.794]
[18]
Lee, S.H.; Lee, S.H.; Lee, J-H.; Kim, J-E. Development, validation, and application of a high-performance liquid chromatography method for the analysis of dissolution samples of telmisartan and rosuvastatin calcium double-layer formulation. Curr. Pharm. Anal., 2021, 17(10), 1282-1292.
[http://dx.doi.org/10.2174/1573412917999201102211941]
[19]
Borman, P; Elder, D. Q2 (R1) validation of analytical procedures. ICH Quality guidelines, 2017, 5, 127-166.
[20]
Lee, Y.C. Method validation for HPLC analysis of related substances in pharmaceutical drug products. In: Analytical Method Validation and Instrument Performance Verification; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2004; pp. 27-49.
[http://dx.doi.org/10.1002/0471463728.ch3]
[21]
Vander Heyden, Y.; Jimidar, M.; Hund, E.; Niemeijer, N.; Peeters, R.; Smeyers-Verbeke, J.; Massart, D.L.; Hoogmartens, J. Determination of system suitability limits with a robustness test. J. Chromatogr. A, 1999, 845(1-2), 145-154.
[http://dx.doi.org/10.1016/S0021-9673(99)00328-3]
[22]
Jenke, D.R. Chromatographic method validation: A review of current practices and procedures. III. Ruggedness, re-validation and system suitability. J. Liq. Chromatogr. Relat. Technol., 1996, 19(12), 1873-1891.
[http://dx.doi.org/10.1080/10826079608014012]
[23]
Tache, F.; Albu, M. Specificity of an analytical HPLC assay method of metformin hydrochloride. Rev. Roum. Chim., 2007, 52, 603-609.
[24]
Araujo, P. Key aspects of analytical method validation and linearity evaluation. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2009, 877(23), 2224-2234.
[http://dx.doi.org/10.1016/j.jchromb.2008.09.030] [PMID: 18929516]
[25]
Uhrovčík, J. Strategy for determination of LOD and LOQ values - Some basic aspects. Talanta, 2014, 119, 178-180.
[http://dx.doi.org/10.1016/j.talanta.2013.10.061] [PMID: 24401401]
[26]
Subramanian, V.B.; Katari, N.K.; Dongala, T.; Jonnalagadda, S.B. Stability‐indicating RP‐HPLC method development and validation for determination of nine impurities in apixaban tablet dosage forms. Robustness study by quality by design approach. Biomed. Chromatogr., 2020, 34(1), e4719.
[http://dx.doi.org/10.1002/bmc.4719] [PMID: 31634417]
[27]
Khan, H. Analytical method development in pharmaceutical research: Steps involved in HPLC method development. Asian J. Pharmaceut. Res., 2017, 7(3), 203-207.
[http://dx.doi.org/10.5958/2231-5691.2017.00031.4]
[28]
Sistla, R.; Tata, V.S.S.K.; Kashyap, Y.V.; Chandrasekar, D.; Diwan, P.V. Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage forms. J. Pharm. Biomed. Anal., 2005, 39(3-4), 517-522.
[http://dx.doi.org/10.1016/j.jpba.2005.04.026] [PMID: 15936912]
[29]
Huang, C.; Song, S.; Liu, W.; Parganiha, P.; Zhuang, P.; Lohani, S.; Alwedi, E.; Ren, H.; Bishara, D.; Chang, H.Y.D. Development of a derivatization RP-HPLC method for determination of sulfuryl chloride in chlorosulfonic acid for gefapixant citrate manufacture. J. Pharm. Biomed. Anal., 2022, 215, 114752.
[http://dx.doi.org/10.1016/j.jpba.2022.114752] [PMID: 35483232]
[30]
Paul, K.; Gowda BH, J.; Shankar, S.J.; Narasimha Reddy, D. Development and validation of simplified RP-HPLC method for quantification of Darunavir in commercial tablets. Mater. Today Proc., 2021, 47, 4155-4161.
[http://dx.doi.org/10.1016/j.matpr.2021.04.444]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy